Document Detail


Strategies for overcoming acquired resistance to epidermal growth factor receptor-targeted therapies in lung cancer.
MedLine Citation:
PMID:  23020725     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Acquired resistance to targeted therapy in epidermal growth factor receptor (EGFR)-mutant lung cancer represents a valuable model for considering strategies of overcoming different types of cellular resistance mechanisms. Using existing data on resistance in EGFR-mutant lung cancer, this review will discuss 3 basic approaches for overcoming resistance to EGFR-targeted therapies: intensification of EGFR inhibition, combination of EGFR inhibitors with other targeted therapies, and changing to anticancer therapies acting via alternate pathways.
Authors:
Geoffrey R Oxnard
Related Documents :
15204265 - Deliberate birth spacing before the fertility transition in europe: evidence from ninet...
23153455 - Overexpression of atp-binding cassette transporter abcg2 as a potential mechanism of ac...
24612015 - Not just grasping at flaws: finding vulnerabilities to develop novel therapies for trea...
7847115 - Bilateral testicular cancer.
21505455 - Diagnosis of head-and-neck cancer from exhaled breath.
12927035 - The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Archives of pathology & laboratory medicine     Volume:  136     ISSN:  1543-2165     ISO Abbreviation:  Arch. Pathol. Lab. Med.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7607091     Medline TA:  Arch Pathol Lab Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1205-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Treatment of ALK-Positive Non-Small Cell Lung Cancer.
Next Document:  Advancing personalized cancer medicine in lung cancer.